Valuation : Fusion Antibodies plc

Market Cap 14.08M 19.14M 16.42M 15.42M 26.57M 1.83B 26.7M 182M 70.7M 921M 71.85M 70.29M 3.05B P/E 2026 *
-16.1x
P/E 2027 * -12.5x
Enterprise Value 14.08M 19.14M 16.42M 15.42M 26.57M 1.83B 26.7M 182M 70.7M 921M 71.85M 70.29M 3.05B EV / Sales 2026 *
6.59x
EV / Sales 2027 * 6.7x
Free-Float
87.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.44%
1 week+10.24%
Current month+15.90%
1 month+5.12%
3 months-13.08%
6 months-19.29%
Current year-19.29%
1 week 10
Extreme 10
11.4
1 month 9.5
Extreme 9.5
11.5
Current year 9.5
Extreme 9.5
17
1 year 9.5
Extreme 9.5
21
3 years 2.8
Extreme 2.8
21
5 years 2.8
Extreme 2.8
138
10 years 2.8
Extreme 2.8
250
Manager TitleAgeSince
Chief Executive Officer 59 2022-08-14
Director of Finance/CFO 52 2023-08-23
Chief Operating Officer - 2023-09-30
Director TitleAgeSince
Chairman 68 2011-08-31
Director/Board Member 50 2011-08-31
Director/Board Member 71 2006-12-31
Date Insider Type Main position Quantity % Market Cap.
2/17/26 Others

Chairman

200,000 0.1760%
1/27/26 Free

Chief Executive Officer

183,438 0.1614%
1/27/26 Free

Chief Technology Officer

125,282 0.1102%
Change 5-day change 1-year change 3-year change Capi.($)
+0.44%+10.24%-24.67%+92.34% 19.14M
-0.22%+0.17%+2.52%+23.41% 50.96B
+1.92%+0.36%+477.97%+550.09% 46.18B
-0.15%-0.28%+21.65%+89.41% 42.73B
+0.81%+4.91%+39.28%+19.41% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
+0.81%+1.77%+31.91%+138.26% 17.28B
-1.08%-3.61% - - 16.43B
-0.05%-0.05%+11.69%+28.50% 14.73B
-0.85%+1.76%+80.26%+47.26% 14.09B
Average -0.06%+2.17%+72.76%+115.57% 27.89B
Weighted average by Cap. +0.05%+1.16%+103.41%+138.86%

Financials

2026 *2027 *
Net sales 2.14M 2.9M 2.49M 2.34M 4.03M 277M 4.05M 27.66M 10.72M 140M 10.89M 10.66M 462M 2.1M 2.85M 2.45M 2.3M 3.96M 272M 3.98M 27.21M 10.55M 137M 10.72M 10.48M 455M
Net income -757K -1.03M -883K -829K -1.43M -98.13M -1.44M -9.81M -3.8M -49.51M -3.86M -3.78M -164M -1.1M -1.49M -1.28M -1.2M -2.07M -142M -2.08M -14.2M -5.5M -71.67M -5.59M -5.47M -237M
Net Debt - -
Logo Fusion Antibodies plc
Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The Company offers an integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development. It offers a range of services including antibody discovery/generation, development, characterization, optimization, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanization using Fusion's proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for downstream use by the customer to produce material for clinical trials. Its Integrated Therapeutic Antibody Services (ITA) offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.
Employees
24
Date Price Change
26-08-27 GBX 11.30 +0.44%
26-08-26 GBX 11.25 0.00%
26-08-25 GBX 11.25 +7.14%
26-08-24 GBX 10.50 0.00%
26-08-21 GBX 10.50 +2.44%

Quarterly revenue - Rate of surprise